Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine
Anna I Guerdjikova,1,2 Nicole Mori,1,2 Leah S Casuto,1,2 Susan L McElroy1,2 1Lindner Center of HOPE, Mason, OH, USA; 2Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA Abstract: Binge eating disorder (BED) is the most common eat...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/928e8fc953654f57973a941040c786e4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:928e8fc953654f57973a941040c786e4 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:928e8fc953654f57973a941040c786e42021-12-02T02:55:33ZNovel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine1178-2021https://doaj.org/article/928e8fc953654f57973a941040c786e42016-04-01T00:00:00Zhttps://www.dovepress.com/novel-pharmacologic-treatment-in-acute-binge-eating-disorder-ndash-rol-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Anna I Guerdjikova,1,2 Nicole Mori,1,2 Leah S Casuto,1,2 Susan L McElroy1,2 1Lindner Center of HOPE, Mason, OH, USA; 2Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA Abstract: Binge eating disorder (BED) is the most common eating disorder and an important public health problem. It is characterized by recurrent episodes of excessive food consumption accompanied by a sense of loss of control over the binge eating behavior without the inappropriate compensatory weight loss behaviors of bulimia nervosa. BED affects both sexes and all age groups and is associated with medical and psychiatric comorbidities. Until recently, self-help and psychotherapy were the primary treatment options for patients with BED. In early 2015, lisdexamfetamine dimesylate, a prodrug stimulant marketed for attention deficit hyperactive disorder, was the first pharmacologic agent to be approved by the US Food and Drug Administration for the treatment of moderate or severe BED in adults. This article summarizes BED clinical presentation, and discusses the pharmacokinetic profile, efficacy, and safety of lisdexamfetamine dimesylate in the treatment of BED in adults. Keywords: binging, overeating, Vyvanse, stimulant, approved medicationGuerdjikova AIMori NCasuto LSMcElroy SLDove Medical PressarticleKey words: binge eatinglisdexamfetamine dimesylatestimulantsovereatingNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2016, Iss Issue 1, Pp 833-841 (2016) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Key words: binge eating lisdexamfetamine dimesylate stimulants overeating Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Key words: binge eating lisdexamfetamine dimesylate stimulants overeating Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Guerdjikova AI Mori N Casuto LS McElroy SL Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine |
| description |
Anna I Guerdjikova,1,2 Nicole Mori,1,2 Leah S Casuto,1,2 Susan L McElroy1,2 1Lindner Center of HOPE, Mason, OH, USA; 2Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA Abstract: Binge eating disorder (BED) is the most common eating disorder and an important public health problem. It is characterized by recurrent episodes of excessive food consumption accompanied by a sense of loss of control over the binge eating behavior without the inappropriate compensatory weight loss behaviors of bulimia nervosa. BED affects both sexes and all age groups and is associated with medical and psychiatric comorbidities. Until recently, self-help and psychotherapy were the primary treatment options for patients with BED. In early 2015, lisdexamfetamine dimesylate, a prodrug stimulant marketed for attention deficit hyperactive disorder, was the first pharmacologic agent to be approved by the US Food and Drug Administration for the treatment of moderate or severe BED in adults. This article summarizes BED clinical presentation, and discusses the pharmacokinetic profile, efficacy, and safety of lisdexamfetamine dimesylate in the treatment of BED in adults. Keywords: binging, overeating, Vyvanse, stimulant, approved medication |
| format |
article |
| author |
Guerdjikova AI Mori N Casuto LS McElroy SL |
| author_facet |
Guerdjikova AI Mori N Casuto LS McElroy SL |
| author_sort |
Guerdjikova AI |
| title |
Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine |
| title_short |
Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine |
| title_full |
Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine |
| title_fullStr |
Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine |
| title_full_unstemmed |
Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine |
| title_sort |
novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine |
| publisher |
Dove Medical Press |
| publishDate |
2016 |
| url |
https://doaj.org/article/928e8fc953654f57973a941040c786e4 |
| work_keys_str_mv |
AT guerdjikovaai novelpharmacologictreatmentinacutebingeeatingdisorderndashroleoflisdexamfetamine AT morin novelpharmacologictreatmentinacutebingeeatingdisorderndashroleoflisdexamfetamine AT casutols novelpharmacologictreatmentinacutebingeeatingdisorderndashroleoflisdexamfetamine AT mcelroysl novelpharmacologictreatmentinacutebingeeatingdisorderndashroleoflisdexamfetamine |
| _version_ |
1718402056830582784 |